Danish Genmab A/S has received market approval in Japan for its anti-CD38 antibody daratumumab (DARZALEX®) as therapy for relapsed or refractory Multiple Myeloma.
ADVERTISEMENT
Neurology specialist Newron Pharmaceuticals S.p.A. (Milan) has raised gross proceeds of CHF 27m through a private placement of new shares via an accelerated book-building process.
Though not reaching the overall surival endpoint in Phase III, the European Commission has granted label extension for Roches checkpoint blocker Tecentriq in two types of metastatic bladder cancer.
French microbiota specialist Da Volterra has received an EIB loan to speed up development of treatments that prevent antibiotic resistance and hospital acquired infections.
A team of US and German researchers has found that neutrophils secrete a regulatory RNA into lung tissue that protects against harmful inflammations.
Healthcare investor Vesalius Biocapital has created a new investment vehicle in collaboration with the Portuguese National Promotional bank (IFD) aimed at investing in Portuguese life science companies.
British T cell receptor specialist Immunocore Ltd will receive a US$40m investment from the the Bill & Melinda Gates Foundation to develop immunotherapies that fight tuberculosis and HIV.
.
The European Medicines Agencys Committee for Medicinal Products for Human Use (CHMP) published the results of its September meeting.
The European Medicine Agencys CHMP has rejected a type II extension application to Santhera Pharmaceuticals coenzyme Q10 analogon idebenone (Raxone) as treatment for patients with Duchenne muscular dystrophy (DMD). Raxone was approved under exceptional circucumstances in September 2015 to treat visual impairment in patients with the rare eye disease LHON.
Artificial intelligence (AI) specialist Sophia Genetics SA (St. Sulpice, Switzerland) raised US$30m in a series D round to foster global expansion of its cancer diagnostics annotation platform SOPHiA AI.